ScottLindhorstMD

Oncology • Charleston, SC

Hematologic Oncology, Neuro-Oncology

Professor of Medicine and Neurosurgery, at Medical University of South Carolina

Join to view full profile

Dr. Lindhorst is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lindhorst's full profile

Already have an account?

Office
171 Ashley Ave
Charleston, SC 29425
Phone+1 843-792-1414

Fax+1 843-876-7766

Summary

Scott Lindhorst, MD, is an oncologist based in Charleston, SC, specializing in Medical and Neuro-Oncology. He completed his medical education at the University of South Alabama College of Medicine and further honed his skills through an Internal Medicine residency, and fellowships in Hematology and Medical Oncology at the University of Alabama at Birmingham Medical Center and Neuro-Oncology at Duke University Hospital. Since 2013, he has been an attending physician at MUSC Health University Medical Center. Dr. Lindhorst has published several notable papers, including studies on glioblastoma and meningioma, and is involved in clinical trials addressing treatments for glioblastoma and other CNS cancers.

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 2012 - 2013
University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
University of Alabama Medical CenterResidency, Internal Medicine, 2006 - 2009
University of South Alabama College of MedicineClass of 2005

Certifications & Licensure

SC State Medical License 2013 - 2025
NC State Medical License 2012 - 2013
AL State Medical License 2008 - 2012
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
United Council for Neurologic SubspecialtiesNeuro-Oncology

Clinical Trials

Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers Start of enrollment: 2009 Nov 01
Completed
Phase 1
Docetaxel and Lycopene in Metastatic Prostate Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 1
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme Start of enrollment: 2014 May 01
Completed
Phase 1, Phase 2
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). Start of enrollment: 2016 Jul 01
Active, not recruiting
Phase 3
Roles: Contact, Principal Investigator
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM Start of enrollment: 2020 Dec 08
Active, not recruiting
Not Applicable
Roles: Contact
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers Start of enrollment: 2017 Jul 13
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Immune Resistance in Glioblastoma: Understanding the Barriers to ICI and CAR-T Cell Therapy.
Thomas Eckert, M S Zobaer, Jessie Boulos, Angela Alexander-Bryant, Tiffany G Baker
Cancers. 2025-01-29
9 citations
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study.
Ayse Bahar Ercan, Melyssa Aronson, Nicholas R Fernandez, Yuan Chang, Adrian Levine
The Lancet. Oncology. 2024-05-01
69 citations
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.
Christina I Tsien, Stephanie L Pugh, Adam P Dicker, Jeffrey J Raizer, Martha M Matuszak
Journal of Clinical Oncology. 2023-02-20

Press Mentions

Hollings Neuro-Oncologists Celebrate New Drug ApprovalAugust 19th, 2024
Young Uterine Cancer Patient Reflects on JourneyJuly 29th, 2024